{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:37:22Z","timestamp":1793162242284,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaccas.2026.109931","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:26:05Z","timestamp":1787225165000},"page":"109931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dasatinib-Induced Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"31","author":[{"given":"Nimisha","family":"Musthafa Hafeesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9750-8131","authenticated-orcid":false,"given":"Gulbadin","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikrishnan","family":"Sivadasanpillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.jaccas.2026.109931_bib1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"129","key":"10.1016\/j.jaccas.2026.109931_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09059180.00003313","article-title":"Drug-induced pulmonary arterial hypertension: a recent outbreak","volume":"22","author":"Montani","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaccas.2026.109931_bib3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemiax in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jaccas.2026.109931_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40259-014-0093-2","article-title":"Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML)","volume":"28","author":"Abruzzese","year":"2014","journal-title":"BioDrugs"},{"issue":"25","key":"10.1016\/j.jaccas.2026.109931_bib5","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaccas.2026.109931_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00217-2017","article-title":"Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study","volume":"50","author":"Weatherald","year":"2017","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.jaccas.2026.109931_bib7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","article-title":"Clinical features of pulmonary arterial hypertension in patients receiving dasatinib","volume":"90","author":"Shah","year":"2015","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.jaccas.2026.109931_bib8","article-title":"Reversible dasatinib-associated pulmonary hypertension managed with dual therapy and Hemodynamic-guided withdrawal","volume":"31","author":"Balmori","year":"2026","journal-title":"JACC Case Rep"},{"issue":"3","key":"10.1016\/j.jaccas.2026.109931_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.70147","article-title":"Dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukaemia: a case report and literature review","volume":"13","author":"Krishnan","year":"2025","journal-title":"Respirol Case Rep"},{"issue":"13","key":"10.1016\/j.jaccas.2026.109931_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIRCULATIONAHA.125.077764","article-title":"Second- and third-generation BCR-ABL tyrosine kinase inhibitors and the risk of pulmonary arterial hypertension: a prevalent new-user design","volume":"153","author":"Jambon-Barbara","year":"2026","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jaccas.2026.109931_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.13508","article-title":"Dasatinib-induced pulmonary arterial hypertension","volume":"84","author":"\u00d6zg\u00fcr Yurtta\u015f","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jaccas.2026.109931_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09031936.00211811","article-title":"Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries","volume":"41","author":"Nagaraj","year":"2013","journal-title":"Eur Respir J"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926030925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926030925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:15:29Z","timestamp":1793160929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084926030925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":12,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666084926030925"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.109931","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib-Induced Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.109931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"109931"}}